Referências
Principais artigos
Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med. 2002 Nov;20(4):365-74. Resumo
Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf). 2005 Jun;62(6):633-43.Texto completo Resumo
Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273-88.Texto completo Resumo
Artigos de referência
1. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006 Aug;65(2):265-73.Texto completo Resumo
2. Serri O, Chik CL, Ur E, et al. Diagnosis and management of hyperprolactinemia. CMAJ. 2003 Sep 16;169(6):575-81.Texto completo Resumo
3. Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med. 2002 Nov;20(4):365-74. Resumo
4. Josimovich JB, Lavenhar MA, Devanesan MM, et al. Heterogeneous distribution of serum prolactin values in apparently healthy young women, and the effects of oral contraceptive medication. Fertil Steril. 1987 May;47(5):785-91. Resumo
5. Ben-Jonathan N, LaPensee CR, LaPensee EW. What can we learn from rodents about prolactin in humans? Endocr Rev. 2008 Feb;29(1):1-41.Texto completo Resumo
6. Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf). 2005 Jun;62(6):633-43.Texto completo Resumo
7. Bole-Feysot C, Goffin V, Edery M, et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev. 1998 Jun;19(3):225-68.Texto completo Resumo
8. Arowojolu AO, Akinloye O, Shittu OB. Serum and seminal plasma prolactin levels in male attenders of an infertility clinic in Ibadan. J Obstet Gynaecol. 2004 Apr;24(3):306-9. Resumo
9. Kanyicska B, Lerant A, Freeman ME. Endothelin is an autocrine regulator of prolactin secretion. Endocrinology. 1998 Dec;139(12):5164-73.Texto completo Resumo
10. Sarkar DK, Kim KH, Minami S. Transforming growth factor-beta 1 messenger RNA and protein expression in the pituitary gland: its action on prolactin secretion and lactotropic growth. Mol Endocrinol. 1992 Nov;6(11):1825-33. Resumo
11. Shah GV, Pedchenko V, Stanley S, et al. Calcitonin is a physiological inhibitor of prolactin secretion in ovariectomized female rats. Endocrinology. 1996 May;137(5):1814-22. Resumo
12. Vilar L, Freitas MC, Naves LA, et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest. 2008 May;31(5):436-44. Resumo
13. Schlechte JA. Long-term management of prolactinomas. J Clin Endocrinol Metab. 2007 Aug;92(8):2861-5.Texto completo Resumo
14. Bevan JS, Burke CW, Esiri MM, et al. Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement. Am J Med. 1987 Jan;82(1):29-32. Resumo
15. Kasantikul V, Shuangshoti S. Pituitary adenomas: immunohistochemical: study of 90 cases. J Med Assoc Thai. 1990 Sep;73(9):514-21. Resumo
16. Bonert VS, Melmed S. Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nat Clin Pract Endocrinol Metab. 2006 Jul;2(7):408-12. Resumo
17. Beressi N, Beressi JP, Cohen R, et al. Lymphocytic hypophysitis. A review of 145 cases. Ann Med Interne (Paris). 1999 Jun;150(4):327-41. Resumo
18. Bhardwaj M, Sharma A, Pal HK. Granulomatous hypophysitis. Neurol India. 2005 Sep;53(3):364-5.Texto completo Resumo
19. Cortet-Rudelli C, Sapin R, Bonneville JF, et al. Etiological diagnosis of hyperprolactinemia. Ann Endocrinol (Paris). 2007 Jun;68(2-3):98-105. Resumo
20. Goel P, Kahkasha, Narang S, et al. Evaluation of serum prolactin level in patients of subclinical and overt hypothyroidism. J Clin Diagn Res. 2015 Jan;9(1):BC15-7.Texto completo Resumo
21. Kyritsi EM, Dimitriadis GK, Angelousi A, et al. The value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome. Eur J Clin Invest. 2018 Jul;48(7):e12961. Resumo
22. Davoudi Z, Araghi F, Vahedi M, et al. Prolactin Level in Polycystic Ovary Syndrome (PCOS): an approach to the diagnosis and management. Acta Biomed. 2021 Nov 3;92(5):e2021291.Texto completo Resumo
23. Saha MT, Saha HH, Niskanen LK, et al. Time course of serum prolactin and sex hormones following successful renal transplantation. Nephron. 2002;92(3):735-7. Resumo
24. Pluguez-Turull CW, Nanyes JE, Quintero CJ, et al. Idiopathic granulomatous mastitis: manifestations at multimodality imaging and pitfalls. Radiographics. 2018 Mar-Apr;38(2):330-56. Resumo
25. Kallenberg GA, Pesce CM, Norman B, et al. Ectopic hyperprolactinemia resulting from an ovarian teratoma. JAMA. 1990 May 9;263(18):2472-4. Resumo
26. Korytnaya E, Liu J, Camelo-Piragua S, et al. Ectopic prolactin secretion from a perivascular epithelioid cell tumor (PEComa). J Clin Endocrinol Metab. 2014 Nov;99(11):3960-4. Resumo
27. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291-314. Resumo
28. Peuskens J, Pani L, Detraux J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014 May;28(5):421-53.Texto completo Resumo
29. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005 Aug;80(8):1050-7.Texto completo Resumo
30. Teoh SK, Lex BW, Mendelson JH, et al. Hyperprolactinemia and macrocytosis in women with alcohol and polysubstance dependence. J Stud Alcohol. 1992 Mar;53(2):176-82. Resumo
31. Coker F, Taylor D. Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management. CNS Drugs. 2010 Jul;24(7):563-74. Resumo
32. Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics: a review. Hum Psychopharmacol. 2010 Jun-Jul;25(4):281-97. Resumo
33. Sarkar DK. Hyperprolactinemia following chronic alcohol administration. Front Horm Res. 2010;38:32-41. Resumo
34. Che Soh NAA, Yaacob NM, Omar J, et al. Global prevalence of macroprolactinemia among patients with hyperprolactinemia: a systematic review and meta-analysis. Int J Environ Res Public Health. 2020 Nov 6;17(21):8199.Texto completo Resumo
35. Kasum M, Orešković S, Čehić E, et al. Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia. Taiwan J Obstet Gynecol. 2017 Dec;56(6):719-24.Texto completo Resumo
36. De Schepper J, Schiettecatte J, Velkeniers B, et al. Clinical and biological characterization of macroprolactinemia with and without prolactin-IgG complexes. Eur J Endocrinol. 2003 Sep;149(3):201-7.Texto completo Resumo
37. Leanos A, Pascoe D, Fraga A, et al. Anti-prolactin autoantibodies in systemic lupus erythematosus patients with associated hyperprolactinemia. Lupus. 1998;7(6):398-403. Resumo
38. Vallette-Kasic S, Morange-Ramos I, Selim A, et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab. 2002 Feb;87(2):581-8.Texto completo Resumo
39. Saleem M, Martin H, Coates P. Prolactin biology and laboratory measurement: an update on physiology and current analytical issues. Clin Biochem Rev. 2018 Feb;39(1):3-16.Texto completo Resumo
40. Hattori N, Ishihara T, Ikekubo K, et al. Autoantibody to human prolactin in patients with idiopathic hyperprolactinemia. J Clin Endocrinol Metab. 1992 Nov;75(5):1226-9. Resumo
41. Hattori N, Ikekubo K, Ishihara T, et al. Effects of anti-prolactin autoantibodies on serum prolactin measurements. Eur J Endocrinol. 1994 May;130(5):434-7. Resumo
42. Sachdev Y, Gopal K, Garg VK, et al. Pituitary apoplexy (spontaneous pituitary necrosis). Postgrad Med J. 1981 May;57(667):289-93.Texto completo Resumo
43. Serhal D, Weil RJ, Hamrahian AH. Evaluation and management of pituitary incidentalomas. Cleve Clin J Med. 2008 Nov;75(11):793-801. Resumo
44. Biousse V, Newman NJ, Oyesiku NM. Precipitating factors in pituitary apoplexy. J Neurol Neurosurg Psychiatry. 2001 Oct;71(4):542-5.Texto completo Resumo
45. Maccagnan P, Macedo CL, Kayath MJ, et al. Conservative management of pituitary apoplexy: a prospective study. J Clin Endocrinol Metab. 1995 Jul;80(7):2190-7. Resumo
46. Nawar RN, AbdelMannan D, Selman WR, et al. Pituitary tumor apoplexy: a review. J Intensive Care Med. 2008 Mar-Apr;23(2):75-90. Resumo
47. Auriemma RS, Pirchio R, Pivonello C, et al. Approach to the patient with prolactinoma. J Clin Endocrinol Metab. 2023 Aug 18;108(9):2400-23.Texto completo Resumo
48. Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273-88.Texto completo Resumo
49. Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023 Dec;19(12):722-40.Texto completo Resumo
50. Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 13th ed. Hoboken, NJ: John Wiley & Sons Ltd; 2018.Texto completo
51. Hammer F, Arlt W. Hypopituitarism [in German]. Internist (Berl). 2004 Jul;45(7):795-811. Resumo
52. Klibanski A, Neer RM, Beitins IZ, et al. Decreased bone density in hyperprolactinemic women. N Engl J Med. 1980 Dec 25;303(26):1511-4. Resumo
53. Biller BM. Hyperprolactinemia. Int J Fertil Womens Med. 1999 Mar-Apr;44(2):74-7. Resumo
54. Fideleff HL, Boquete HR, Sequera A, et al. Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches. J Pediatr Endocrinol Metab. 2000 Mar;13(3):261-7. Resumo
55. Serri O, Li L, Mamputu JC, et al. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf). 2006 Apr;64(4):366-70. Resumo
56. Arslan MS, Topaloglu O, Sahin M, et al. Preclinical atherosclerosis in patients with prolactinoma. Endocr Pract. 2014 May;20(5):447-51. Resumo
57. Wagner R, Heni M, Linder K, et al. Age-dependent association of serum prolactin with glycaemia and insulin sensitivity in humans. Acta Diabetol. 2014 Feb;51(1):71-8. Resumo
58. Whyte MB, Pramodh S, Srikugan L, et al. Importance of cannulated prolactin test in the definition of hyperprolactinaemia. Pituitary. 2015 Jun;18(3):319-25. Resumo
59. Beda-Maluga K, Pisarek H, Komorowski J, et al. Evaluation of hyperprolactinaemia with the use of the intervals for prolactin after macroforms separation. J Physiol Pharmacol. 2014 Jun;65(3):359-64.Texto completo Resumo
60. Hall WA, Luciano MG, Doppman JL, et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med. 1994 May 15;120(10):817-20. Resumo
61. Rand T, Kink E, Sator M, et al. MRI of microadenomas in patients with hyperprolactinaemia. Neuroradiology. 1996 Nov;38(8):744-6. Resumo
62. Biller BM, Luciano A, Crosignani PG, et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med. 1999 Dec;44(12 Suppl):1075-84. Resumo
63. Karavitaki N, Thanabalasingham G, Shore HC, et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf). 2006 Oct;65(4):524-9. Resumo
64. Kawaguchi T, Ogawa Y, Tominaga T. Diagnostic pitfalls of hyperprolactinemia: the importance of sequential pituitary imaging. BMC Res Notes. 2014 Aug 20;7:555.Texto completo Resumo
65. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000 Feb;85(2):526-9.Texto completo Resumo
66. Olukoga AO, Kane JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol (Oxf). 1999 Jul;51(1):119-26. Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal